Development Journey-BIOTECH PHARMACEUTICAL CO., LTD_EGF Vaccine

Home
About Us
About Us

BPL is a high-tech China-Cuba joint venture among first group engaged in the development, production and sales of monoclonal antibodies in China.
S&T
S&T

International-standard humanized monoclonal antibody preparation processes and large-scale, continuous mammalian cell culture technology.
- Research Areas
- Technology Platforms
Research and Development
Research and Development

China has developed nivolumab, a humanized monoclonal antibody drug (trade name: TaiXinSheng), for the treatment of malignant tumors.
Blog
Blog

Integrating industry-related media coverage as well as the company’s various activities and updates.
- Company News
- Media Reports
Join Us
Join Us

Boasting a postdoctoral research workstation and diverse career opportunities, we sincerely invite talented individuals from all fields to join Baite.
- Post-Doctoral Center
Contact Us
Contact Us

ThaiXinLife Consultation Hotline: +86 4006592330
Company Main Line: +86-10-51571020
- Contact Us

中

November 2024

Nimotuzumab Head and Neck Tumor Indication Added to National Medical Insurance Catalog

January 2024

Nimotuzumab (Taixinsheng®) Receives Marketing Approval for Head and Neck Tumor Indication

June 2023

Nimotuzumab (Therasine®) Receives Marketing Approval for Pancreatic Cancer Indication

May 2023

Biotech Pharma Named a Municipal Model of Integrity

April 2023

Cuban Deputy Prime Minister Perdomo leads delegation to visit Biotech Pharma

July 2022

Biotech Pharma Passes Annual Operational Evaluation of Beijing Enterprise Technology Center

June 2022

The study comparing nivolumab combined with gemcitabine to gemcitabine alone for K-Ras wild-type locally advanced or metastatic pancreatic cancer was selected for an oral presentation and a Breakthrough Research session at ASCO 2022.

May 2022

A delegation led by Carlos Miguel Pérez Hernández, Cuba's ambassador to China, visited Biotech Pharma.

March 2022

Biotech Pharma awarded the Beijing Municipality's "Little Giant" title for specialized, sophisticated, and innovative enterprises.

December 2021

Chairman Bai Xianhong attended the event commemorating Castro and was awarded the "China-Cuba Diplomatic Relations 60th Anniversary Medal" and the "China-Cuba Diplomatic Relations 60th Anniversary Certificate of Honor."

December 2021

"Cloud" signing ceremony for the 2021–2023 collaborative project with the Cuban Center for Molecular Immunology

October 2021

Biotech Pharma's groundbreaking scientific achievement, TaiXinSheng, showcased at the National "13th Five-Year Plan" Science and Technology Innovation Achievement Exhibition.

May 2021

Biotech Pharma exports its first large-scale monoclonal antibody bulk substance to Cuba.

2020

The 4000L continuous perfusion cell culture production line has passed the Beijing Bureau's compliance inspection.

2020

The 4000L continuous perfusion cell culture production line has received national approval for production.

November 2020

Chairman Bai Xianhong attends the "Cuba-China" Trade Forum in Shanghai.

October 2020

Vice Secretary-General Qu Fenghong of the National Committee of the Chinese People's Political Consultative Conference, along with Director Jiao Hong and her delegation from the National Medical Products Administration, visited our company for an inspection.

October 2020